TT5

Plus, news about Apollo Therapeutics, Reunion Neuroscience, Basilea, Tafalgie Therapeutics, Areteia Therapeutics and Avidity Biosciences: 🇨🇳 Two more biotechs look to IPO in Hong Kong: Ark Biopharmaceutical in Shanghai and Atom Therapeutics in Hangzhou joined the queue of Chinese drug developers looking to go public on the Hong Kong Stock Exchange. Founded in 2013, ArkBio is waiting for approval in China next year for an RSV treatment and a small molecule for ADHD. It also has programs in development for IPF , COPD and influenza and has in-licensed candidates from Roche and Commave Therapeutics. Meanwhile, Atom has treatments for various forms of gout , hyperuricemia and chronic kidney disease in late- and mid-stage trials. — Kyle LaHucik 🔬 Aptevo Therapeutics’ stock jumps on early AML data: The Seattle company reported a 100% remission rate in six newly diagnosed AML patients who received mipletamig, its CD123xCD3 bispecific, on top of the standard treatments of AbbVie and Roche’s Venclexta and azacitidine. These patients were given the highest dose (27 mcg) thus far of mipletamig in the Phase 1b/2 trial. Aptevo said no cases of cytokine release syndrome have been reported in frontline patients treated with its drug. The biotech’s shares $APVO jumped about 30% Tuesday morning. — Lei Lei Wu ✅ Apollo Therapeutics shares mid-stage atopic dermatitis data: The biotech’s IL-18 targeting antibody, called camoteskimab, produced a statistically significant reduction in the eczema area and severity index versus placebo at 16 weeks. Scores for the two arms were “clearly separated” at four weeks. Apollo plans to share detailed results at an upcoming scientific conference. — Ayisha Sharma 🧠 Reunion Neuroscience gets $30M Series A extension: The additional cash brings the total amount raised to $133 million. Reunion said the money will help fund a Phase 2 study in adjustment disorder in cancer and other diseases, while also supporting the launch of a separate trial for generalized anxiety disorder. — Max Gelman 🦠 Basilea gets $25M from BARDA: The company is developing a pair of antifungal treatments: fosmanogepix and BAL2062. It’s evaluating fosmanogepix in yeast infections and both drugs for mold infections. — Jaimy Lee 💶 Non-opioid pain biotech secures €12 million in Series A: Tafalgie Therapeutics, based in Marseille, plans to use the proceeds to advance its lead pain candidate, TT5, through Phase 2a development, according to a release emailed to Endpoints News . TT5 is a peptide derivative of a naturally occurring protein called TAFA4, which modulates pain signals as they move between the peripheral and central nervous systems. — Ayisha Sharma 🫁 Areteia Therapeutics toplines Phase 3 trial in eosinophilic asthma: The company studied an oral drug called dexpramipexole, which improved patients’ lung function by a statistically significant margin compared to placebo. Researchers averaged lung function measurements after 20 and 24 weeks. No specific figures were disclosed. — Max Gelman 💰 Avidity Biosciences ended up raising $690 million in its public offering. — Jaimy Lee